Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model

Vessel co-option in cancer

(2019) Elizabeth A. Kuczynski et al.   Nature Reviews Clinical Oncology

Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway

(2018) Yoshiro Itatani et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

(2017) Martina Schmittnaegel et al.   Science Translational Medicine

Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models

(2016) Victoria L Bridgeman et al.   JOURNAL OF PATHOLOGY

The use of CrossMAb technology for the generation of bi- and multispecific antibodies

(2016) Christian Klein et al.   mAbs

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

(2016) Sophia Frentzas et al.   NATURE MEDICINE

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

(2016) Jonas Kloepper et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside

(2016) Marlous Arjaans et al.   Oncotarget

Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer

(2014) Hanna Sallinen et al.   BMC CANCER

Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels

(2013) Stefano Kim et al.   BMC CANCER

Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

(2013) Y. Kienast et al.   CLINICAL CANCER RESEARCH

A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors

(2013) Markus Thomas et al.   PLoS One

Correction: The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review

(2013) Limor Amit et al.   PLoS One

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

(2011) W. Schaefer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy

(2010) V Goede et al.   BRITISH JOURNAL OF CANCER

Pathways Mediating Resistance to Vascular Endothelial Growth Factor-Targeted Therapy

(2008) L. M. Ellis et al.   CLINICAL CANCER RESEARCH